ClinicalTrials.gg
Not yet recruitingNCT07409168Updated Apr 28, 2026

Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL

An observational study in Natural Killer/T-cell Lymphoma, sponsored by Sun Yat-sen University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Sun Yat-sen University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphoma, T-Cell · Sun Yat-sen University.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 11th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

6 of the 11 studies in Lymphoma, T-Cell by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lymphoma, T-Cell by Sun Yat-sen University, or all of them as a file.
02

Study summary

This is a multicenter prospective study to develop and validate a multimodal, deep learning-based model for predicting treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line asparaginase-based therapy.

03

Conditions studied

  • Natural Killer/T-cell Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adult patients with pathologically confirmed extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line asparaginase-based chemotherapy or chemoradiotherapy, with available pretreatment MRI or H\&E-stained whole-slide pathology images. Patients will be prospectively followed for treatment response and survival outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age ≥ 18 years.
  • 2. confirmed extranodal natural killer/T-cell lymphoma (NKTCL) according to the World Health Organization (WHO) classification.
  • 3. Patients who are planned to receive asparaginase-based chemotherapy or chemoradiotherapy.
  • 4. Patients who have either contrast-enhanced MRI of the nasopharynx obtained as part of routine clinical care or pretreatment whole-slide images (WSI) of tumor tissue from hematoxylin and eosin (H\&E)-stained sections available for analysis.
  • 5. Ability to understand the study and provide written (ICF).

Exclusion criteria

Exclusion Criteria:

  • 1. History of other malignant tumors.
  • 2. Patients with psychiatric disorders or those unable to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • First-line Asparaginase-based Treatment Cohort

    Participants in this cohort are patients with extranodal natural killer/T-cell lymphoma (NKTCL) who are planned to receive standard first-line asparaginase-based chemotherapy according to institutional practice. Pretreatment clinical data, contrast-enhanced magnetic resonance imaging (MRI) of the nasopharynx and neck, and digital pathology images from hematoxylin and eosin (H\&E)-stained tumor sections will be collected. Patients will be followed for progression-free survival and overall survival according to routine follow-up schedule.

06

What researchers measure

Primary outcomes

  1. Predictive accuracy of first-line treatment response (CR vs non-CR) according to Lugano 2014 criteria

    The primary outcome is the predictive performance of the multimodal deep learning model for first-line treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL). Treatment response is assessed according to the Lugano 2014 criteria. Model performance will be evaluated by receiver operating characteristic (ROC) analysis and quantified using the area under the curve (AUC), accuracy, sensitivity, specificity, positive predictive value, and negative predictive value by comparing model predictions with observed clinical response.

    Time frame: From baseline to disease response and follow-up assessments, up to 3 years.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07409168
Responsible party
Qingqing Cai (chief phycisian, Sun Yat-sen University) — Principal investigator
First posted
Feb 13, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 28, 2026

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
0208734282

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion